S&P 500   3,852.36
DOW   32,920.46
QQQ   296.26
Why Lucid Spiked Nearly 100% In One Day
Is This The End of Capitalism? (Ad)
Is Buying an Aged Corporation a Good Idea?
MarketBeat Week in Review – 1/23- 1/27
Is This The End of Capitalism? (Ad)
Visa, L3Harris rise; Intel, Eastman Chemical fall
How major US stock indexes fared Friday 1/27/2023
Is This The End of Capitalism? (Ad)
Closing prices for crude oil, gold and other commodities
Stocks drift as strong week for Wall Street heads for close
S&P 500   3,852.36
DOW   32,920.46
QQQ   296.26
Why Lucid Spiked Nearly 100% In One Day
Is This The End of Capitalism? (Ad)
Is Buying an Aged Corporation a Good Idea?
MarketBeat Week in Review – 1/23- 1/27
Is This The End of Capitalism? (Ad)
Visa, L3Harris rise; Intel, Eastman Chemical fall
How major US stock indexes fared Friday 1/27/2023
Is This The End of Capitalism? (Ad)
Closing prices for crude oil, gold and other commodities
Stocks drift as strong week for Wall Street heads for close
S&P 500   3,852.36
DOW   32,920.46
QQQ   296.26
Why Lucid Spiked Nearly 100% In One Day
Is This The End of Capitalism? (Ad)
Is Buying an Aged Corporation a Good Idea?
MarketBeat Week in Review – 1/23- 1/27
Is This The End of Capitalism? (Ad)
Visa, L3Harris rise; Intel, Eastman Chemical fall
How major US stock indexes fared Friday 1/27/2023
Is This The End of Capitalism? (Ad)
Closing prices for crude oil, gold and other commodities
Stocks drift as strong week for Wall Street heads for close
S&P 500   3,852.36
DOW   32,920.46
QQQ   296.26
Why Lucid Spiked Nearly 100% In One Day
Is This The End of Capitalism? (Ad)
Is Buying an Aged Corporation a Good Idea?
MarketBeat Week in Review – 1/23- 1/27
Is This The End of Capitalism? (Ad)
Visa, L3Harris rise; Intel, Eastman Chemical fall
How major US stock indexes fared Friday 1/27/2023
Is This The End of Capitalism? (Ad)
Closing prices for crude oil, gold and other commodities
Stocks drift as strong week for Wall Street heads for close

Trevi Therapeutics - TRVI Stock Forecast, Price & News

$2.46
+0.13 (+5.58%)
(As of 01/27/2023 12:00 AM ET)
Add
Compare
Today's Range
$2.30
$2.61
50-Day Range
$1.74
$2.82
52-Week Range
$0.46
$4.68
Volume
45,202 shs
Average Volume
42,472 shs
Market Capitalization
$147.40 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$8.25

Trevi Therapeutics MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
235.4% Upside
$8.25 Price Target
Short Interest
Healthy
0.16% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
1.90mentions of Trevi Therapeutics in the last 14 days
Based on 2 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($0.54) to ($0.45) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.44 out of 5 stars

Medical Sector

207th out of 1,055 stocks

Pharmaceutical Preparations Industry

96th out of 519 stocks


TRVI stock logo

About Trevi Therapeutics (NASDAQ:TRVI) Stock

Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization Haduvio to treat serious neurologically mediated conditions. It includes treatment of chronic pruritus associated with prurigo nodularis and chronic cough in patients with idiopathic pulmonary fibrosis, and levodopa-induced dyskinesia in patients with Parkinson's disease. The company was founded by Thomas R. Sciascia and Jennifer L. Good in March 2011 and is headquartered in New Haven, CT.

Receive TRVI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Trevi Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

TRVI Stock News Headlines

Is This The End of Capitalism?
EXPOSED: The establishment plot to disenfranchise and impoverish millions of Americans…
TRVI Trevi Therapeutics, Inc.
Is This The End of Capitalism?
EXPOSED: The establishment plot to disenfranchise and impoverish millions of Americans…
/C O R R E C T I O N -- Trevi Therapeutics, Inc./
Trevi Therapeutics Announces Proposed Public Offering
Trevi Therapeutics: Moving Forward
See More Headlines
Receive TRVI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Trevi Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

TRVI Company Calendar

Last Earnings
11/10/2022
Today
1/28/2023
Next Earnings (Estimated)
3/16/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:TRVI
Fax
N/A
Employees
24
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$8.25
High Stock Price Forecast
$10.00
Low Stock Price Forecast
$6.00
Forecasted Upside/Downside
+235.4%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
4 Analysts

Profitability

Net Income
$-33,940,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$0.66 per share

Miscellaneous

Free Float
36,241,000
Market Cap
$147.40 million
Optionable
Not Optionable
Beta
0.69

Key Executives

  • Jennifer L. Good
    President, Chief Executive Officer & Director
  • Lisa Delfini
    Chief Financial Officer
  • Thomas R. Sciascia
    Chief Science Officer
  • Danine Summers
    Vice President-Medical Affairs
  • David J. Clark
    Chief Medical Officer













TRVI Stock - Frequently Asked Questions

Should I buy or sell Trevi Therapeutics stock right now?

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Trevi Therapeutics in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" TRVI shares.
View TRVI analyst ratings
or view top-rated stocks.

What is Trevi Therapeutics' stock price forecast for 2023?

4 analysts have issued 1 year target prices for Trevi Therapeutics' shares. Their TRVI share price forecasts range from $6.00 to $10.00. On average, they predict the company's stock price to reach $8.25 in the next year. This suggests a possible upside of 235.4% from the stock's current price.
View analysts price targets for TRVI
or view top-rated stocks among Wall Street analysts.

How have TRVI shares performed in 2023?

Trevi Therapeutics' stock was trading at $1.93 at the beginning of the year. Since then, TRVI stock has increased by 27.5% and is now trading at $2.46.
View the best growth stocks for 2023 here
.

When is Trevi Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, March 16th 2023.
View our TRVI earnings forecast
.

How were Trevi Therapeutics' earnings last quarter?

Trevi Therapeutics, Inc. (NASDAQ:TRVI) released its quarterly earnings data on Thursday, November, 10th. The company reported ($0.12) EPS for the quarter, topping the consensus estimate of ($0.15) by $0.03.

What other stocks do shareholders of Trevi Therapeutics own?
When did Trevi Therapeutics IPO?

(TRVI) raised $70 million in an initial public offering on Tuesday, May 7th 2019. The company issued 4,700,000 shares at $14.00-$16.00 per share. SVB Leerink, Stifel and BMO Capital Markets acted as the underwriters for the IPO and Needham & Company was co-manager.

What is Trevi Therapeutics' stock symbol?

Trevi Therapeutics trades on the NASDAQ under the ticker symbol "TRVI."

How do I buy shares of Trevi Therapeutics?

Shares of TRVI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Trevi Therapeutics' stock price today?

One share of TRVI stock can currently be purchased for approximately $2.46.

How much money does Trevi Therapeutics make?

Trevi Therapeutics (NASDAQ:TRVI) has a market capitalization of $147.41 million. The company earns $-33,940,000.00 in net income (profit) each year or ($0.78) on an earnings per share basis.

How can I contact Trevi Therapeutics?

Trevi Therapeutics' mailing address is 195 CHURCH STREET 14TH FLOOR, NEW HAVEN CT, 06510. The official website for the company is www.trevitherapeutics.com. The company can be reached via phone at (203) 304-2499 or via email at peter.vozzo@westwicke.com.

This page (NASDAQ:TRVI) was last updated on 1/28/2023 by MarketBeat.com Staff